Advertisement
Advertisement
U.S. markets close in 5 hours 30 minutes
Advertisement
Advertisement
Advertisement
Advertisement
WEF 2022

Yahoo Finance is in Davos! Get the latest updates here

Arvinas, Inc. (ARVN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
41.61-1.52 (-3.52%)
As of 10:30AM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Previous Close43.13
Open43.09
Bid41.19 x 1300
Ask41.25 x 1200
Day's Range40.99 - 44.36
52 Week Range37.41 - 108.47
Volume38,830
Avg. Volume497,355
Market Cap2.212B
Beta (5Y Monthly)2.05
PE Ratio (TTM)N/A
EPS (TTM)-4.18
Earnings DateAug 03, 2022 - Aug 08, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est106.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ARVN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Arvinas, Inc.
    Daily – Vickers Top Buyers & Sellers for 05/11/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    13 days agoArgus Research
View more
  • TipRanks

    Investing in These 3 Healthcare Stocks Could Double Your Money, Says Credit Suisse

    On Wall Street, some things never change. High inflation or not, the fact of the matter remains that healthcare stocks are the epitome of risk/reward plays. Why? It comes down to the nature of the industry itself. Healthcare companies are unique in that their financial performances aren’t necessarily the most important piece of the puzzle. Rather, a few key factors like clinical data readouts or regulatory approvals indicate whether or not a particular name will be able to generate sustainable r

  • PR Newswire

    GNS Healthcare and Arvinas Enter into Neuroscience Drug Discovery Collaboration

    GNS Healthcare, the leader in the use of "Virtual Patients", Causal AI and simulation technology for biopharmaceutical companies, today announced a collaboration with Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, to generate insights to help accelerate drug development for neurodegenerative diseases.

  • Zacks

    Arvinas, Inc. (ARVN) Reports Q1 Loss, Lags Revenue Estimates

    Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -41.18% and 23.55%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Advertisement
Advertisement